(NASDAQ: IRON) Disc Medicine's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 112.96%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 23%.
Disc Medicine's revenue in 2026 is $0.On average, 14 Wall Street analysts forecast IRON's revenue for 2026 to be $1,549,379,899, with the lowest IRON revenue forecast at $414,345,778, and the highest IRON revenue forecast at $2,798,646,010. On average, 13 Wall Street analysts forecast IRON's revenue for 2027 to be $4,534,926,961, with the lowest IRON revenue forecast at $2,079,127,922, and the highest IRON revenue forecast at $7,343,161,512.
In 2028, IRON is forecast to generate $10,770,876,222 in revenue, with the lowest revenue forecast at $4,184,227,956 and the highest revenue forecast at $16,183,494,449.